• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血红蛋白水平与血浆粪卟啉原 I 浓度的关系作为 OATP1B 表型分析的内源性探针。

Relationship of hemoglobin level and plasma coproporphyrin-I concentrations as an endogenous probe for phenotyping OATP1B.

机构信息

Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.

Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

出版信息

Clin Transl Sci. 2021 Jul;14(4):1403-1411. doi: 10.1111/cts.12996. Epub 2021 May 7.

DOI:10.1111/cts.12996
PMID:33650309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8301560/
Abstract

Plasma coproporphyrin-I (CP-I) concentration is used as a sensitive and selective endogenous probe for phenotyping organic anion transporting polypeptides 1B (OATP1B) activity in many studies. CP-I is produced in the process of heme synthesis, but the relationship between plasma CP-I concentrations and heme synthesis activity is unknown. In this study, we evaluated the relationship between plasma CP-I concentration and hemoglobin level as a biomarker of heme synthesis activity. The data of 391 subjects selected from the Japanese general population were analyzed. One hundred twenty-six participants had OATP1B115 allele, 11 of whom were homozygous (OATP1B115/15). Multiple regression analysis identified hemoglobin level as an independent variable associated with plasma CP-I concentration (p < 0.0001). A significant positive correlation was observed between hemoglobin level and plasma CP-I concentration in participants without OATP1B115 allele (n = 265; r  = 0.35, p < 0.0001) and with OATP1B1*15 allele (n = 126; r  =0.27, p = 0.0022). However, Kruskal-Wallis test showed no large difference in Kruskal-Wallis statistics between the distribution of plasma CP-I concentrations and that of ratio of plasma CP-I to hemoglobin among six OATP1B1 polymorphism groups. These findings suggest that the hemoglobin level seems to reflect biosynthesis of CP-I. However, correction by hemoglobin level is not required when using basal plasma CP-I concentration for phenotyping OATP1B activity.

摘要

血浆粪卟啉 I(CP-I)浓度被用作许多研究中鉴定有机阴离子转运多肽 1B(OATP1B)活性的敏感和选择性内源性探针。CP-I 是在血红素合成过程中产生的,但血浆 CP-I 浓度与血红素合成活性之间的关系尚不清楚。在这项研究中,我们评估了血浆 CP-I 浓度与血红蛋白水平作为血红素合成活性生物标志物之间的关系。分析了从日本普通人群中选择的 391 名受试者的数据。126 名参与者携带 OATP1B115 等位基因,其中 11 名是纯合子(OATP1B115/15)。多元回归分析确定血红蛋白水平是与血浆 CP-I 浓度相关的独立变量(p<0.0001)。在没有 OATP1B115 等位基因的参与者(n=265;r=0.35,p<0.0001)和携带 OATP1B1*15 等位基因的参与者(n=126;r=0.27,p=0.0022)中,观察到血红蛋白水平与血浆 CP-I 浓度之间存在显著正相关。然而,Kruskal-Wallis 检验显示,在六个 OATP1B1 多态性组中,血浆 CP-I 浓度的分布与血浆 CP-I 与血红蛋白比值的分布之间的 Kruskal-Wallis 统计值没有很大差异。这些发现表明,血红蛋白水平似乎反映了 CP-I 的生物合成。然而,在用基础血浆 CP-I 浓度进行 OATP1B 活性表型分析时,不需要通过血红蛋白水平进行校正。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/86e9548ae11d/CTS-14-1403-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/be7dac67dae0/CTS-14-1403-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/ec5cf39c5717/CTS-14-1403-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/6abf0a2c300e/CTS-14-1403-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/86e9548ae11d/CTS-14-1403-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/be7dac67dae0/CTS-14-1403-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/ec5cf39c5717/CTS-14-1403-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/6abf0a2c300e/CTS-14-1403-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b20/8301560/86e9548ae11d/CTS-14-1403-g002.jpg

相似文献

1
Relationship of hemoglobin level and plasma coproporphyrin-I concentrations as an endogenous probe for phenotyping OATP1B.血红蛋白水平与血浆粪卟啉原 I 浓度的关系作为 OATP1B 表型分析的内源性探针。
Clin Transl Sci. 2021 Jul;14(4):1403-1411. doi: 10.1111/cts.12996. Epub 2021 May 7.
2
Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.日本人种群体中 OATP1B1*15 等位基因与血浆粪卟啉原 I 浓度显著升高相关。
Clin Transl Sci. 2021 Jan;14(1):382-388. doi: 10.1111/cts.12889. Epub 2020 Oct 5.
3
Factors Influencing Plasma Coproporphyrin-I Concentration as Biomarker of OATP1B Activity in Patients With Rheumatoid Arthritis.类风湿关节炎患者中影响血浆粪卟啉原-I浓度作为OATP1B活性生物标志物的因素
Clin Pharmacol Ther. 2021 Oct;110(4):1096-1105. doi: 10.1002/cpt.2375. Epub 2021 Aug 10.
4
Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.检测人血浆粪卟啉中丙磺舒对有机阴离子转运多肽 1B 的抑制作用。
Drug Metab Dispos. 2020 Oct;48(10):841-848. doi: 10.1124/dmd.120.000076. Epub 2020 Jul 28.
5
Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.粪卟啉作为OATP1B临床内源性标志物的进一步评估
J Clin Pharmacol. 2021 Aug;61(8):1027-1034. doi: 10.1002/jcph.1817. Epub 2021 Apr 21.
6
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.粪卟啉原 I 可作为 OATP1B1 抑制的内源性生物标志物:基于 glecaprevir/pibrentasvir 临床研究的评估。
Clin Transl Sci. 2021 Jan;14(1):373-381. doi: 10.1111/cts.12888. Epub 2020 Oct 24.
7
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.进一步的研究支持粪卟啉 I 和 III 作为新型临床生物标志物用于评估有机阴离子转运多肽 1B1 和 OATP1B3 抑制潜力。
Drug Metab Dispos. 2018 Aug;46(8):1075-1082. doi: 10.1124/dmd.118.081125. Epub 2018 May 18.
8
Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.原卟啉作为预测 OATP1B 介导的药物相互作用从轻度到重度的敏感生物标志物的临床研究。
Clin Pharmacokinet. 2018 Dec;57(12):1559-1570. doi: 10.1007/s40262-018-0648-3.
9
Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.熊去氧胆酸处理食蟹猴后有机阴离子转运多肽 1B 表达受抑制和血浆粪卟啉水平升高提示 OATP1B 下调。
Drug Metab Dispos. 2022 Aug;50(8):1077-1086. doi: 10.1124/dmd.122.000875. Epub 2022 May 30.
10
Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.基于生物标志物的有机阴离子转运多肽 1B 介导的药物相互作用的模型引导风险评估。
Clin Pharmacol Ther. 2022 Feb;111(2):404-415. doi: 10.1002/cpt.2434. Epub 2021 Oct 22.

引用本文的文献

1
Genotype, Ethnicity, and Drug-Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin-I Story.基因型、种族和药物-药物相互作用建模作为验证转运体生物标志物生理药代动力学模型的手段:粪卟啉-I的故事
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):941-953. doi: 10.1002/psp4.70008. Epub 2025 Mar 10.
2
Altered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病患者胆汁酸和粪卟啉原-I代谢异常
Br J Clin Pharmacol. 2025 Feb;91(2):353-364. doi: 10.1111/bcp.16221. Epub 2024 Sep 24.
3
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.

本文引用的文献

1
Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.非酒精性脂肪性肝炎中转运蛋白活性的变化:采用血浆粪卟啉原Ⅰ和Ⅲ评估。
J Pharmacol Exp Ther. 2021 Jan;376(1):29-39. doi: 10.1124/jpet.120.000291. Epub 2020 Oct 30.
2
Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.日本人种群体中 OATP1B1*15 等位基因与血浆粪卟啉原 I 浓度显著升高相关。
Clin Transl Sci. 2021 Jan;14(1):382-388. doi: 10.1111/cts.12889. Epub 2020 Oct 5.
3
Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
细胞色素 P450 酶和转运体在抗丙型肝炎抗病毒药物asunaprevir、daclatasvir 和 beclabuvir 的生物转化和转运中的作用:肝脏疾病、种族和药物相互作用对安全性和疗效的影响。
Curr Drug Metab. 2024;25(2):96-109. doi: 10.2174/0113892002288832240213095622.
4
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans.血浆粪卟啉原 I 和 III 作为 OATP1B1 生物标志物在人体中的表现。
Clin Pharmacol Ther. 2021 Dec;110(6):1622-1632. doi: 10.1002/cpt.2429. Epub 2021 Oct 15.
使用超高效液相色谱-串联质谱法同时定量测定人血浆中的粪卟啉-I和3-羧基-4-甲基-5-丙基-2-呋喃丙酸
J Pharm Biomed Anal. 2020 May 30;184:113202. doi: 10.1016/j.jpba.2020.113202. Epub 2020 Feb 24.
4
Donor Deferral Due to Low Hemoglobin-An Updated Systematic Review.因血红蛋白水平低导致的献血者延期——一项最新的系统评价
Transfus Med Rev. 2020 Jan;34(1):10-22. doi: 10.1016/j.tmrv.2019.10.002. Epub 2019 Oct 31.
5
Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.利福平在健康志愿者中对 OATP1B 的剂量依赖性抑制作用:候选生物标志物和 OATP1B 探针药物的综合评估。
Clin Pharmacol Ther. 2020 Apr;107(4):1004-1013. doi: 10.1002/cpt.1695. Epub 2020 Jan 1.
6
Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.利福平的扩展生理药代动力学模型,用于预测通过包括有机阴离子转运多肽 1B 诱导在内的复杂机制与药物和内源性生物标志物的相互作用。
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):845-857. doi: 10.1002/psp4.12457. Epub 2019 Sep 5.
7
Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.芬布鲁替尼的复杂药物相互作用及利用转运体内源性生物标志物阐明药物相互作用机制
Clin Pharmacol Ther. 2020 Jan;107(1):269-277. doi: 10.1002/cpt.1599. Epub 2019 Sep 16.
8
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.在首次人体剂量递增研究中,用内源性生物标志物评估 GDC-0810 的药代动力学和转运体介导的药物相互作用。
Drug Metab Dispos. 2019 Sep;47(9):966-973. doi: 10.1124/dmd.119.087924. Epub 2019 Jul 2.
9
Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease.终末期肾病患者活体肾移植后 OATP1B 活性的恢复。
Pharm Res. 2019 Feb 26;36(4):59. doi: 10.1007/s11095-019-2593-8.
10
PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.PBPK 模型研究粪卟啉原 I 作为药物相互作用的内源性生物标志物在抑制肝 OATP1B1 和 OATP1B3 中的作用
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):739-747. doi: 10.1002/psp4.12348. Epub 2018 Sep 30.